Lexeo Therapeutics Inc. [LXEO] stock is trading at $10.78, up 3.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXEO shares have gain 11.48% over the last week, with a monthly amount drifted -15.05%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lexeo Therapeutics Inc. [NASDAQ: LXEO] stock has seen the most recent analyst activity on June 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $28. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 06, 2024, and set its price target to $22. On November 28, 2023, Stifel initiated with a Buy rating and assigned a price target of $20 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $22 on November 28, 2023. Leerink Partners initiated its recommendation with a Outperform and recommended $19 as its price target on November 28, 2023. JP Morgan started tracking with a Overweight rating for this stock on November 28, 2023, and assigned it a price target of $20. In a note dated November 28, 2023, Chardan Capital Markets initiated an Buy rating and provided a target price of $23 on this stock.
Lexeo Therapeutics Inc. [LXEO] stock has fluctuated between $9.00 and $22.33 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Lexeo Therapeutics Inc. [NASDAQ: LXEO] shares were valued at $10.78 at the most recent close of the market. An investor can expect a potential return of 159.74% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -1.03 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.26 points at the first support level, and at 9.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.09, and for the 2nd resistance point, it is at 11.40.
Ratios To Look Out For
For context, Lexeo Therapeutics Inc.’s Current Ratio is 9.38. Also, the Quick Ratio is 9.38, while the Cash Ratio stands at 9.27.
Transactions by insiders
Recent insider trading involved Townsend Richard Nolan, Chief Executive Officer, that happened on Sep 10 ’24 when 5000.0 shares were sold. Director, Richard Nolan Townsend completed a deal on Sep 10 ’24 to buy 12500.0 shares. Meanwhile, Chief Executive Officer Townsend Richard Nolan sold 5000.0 shares on Aug 12 ’24.
